Cambridge Investment Research Advisors Inc. Raises Position in GlaxoSmithKline plc (GSK)

Cambridge Investment Research Advisors Inc. grew its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 10.7% in the first quarter, according to its most recent filing with the SEC. The fund owned 119,385 shares of the pharmaceutical company’s stock after acquiring an additional 11,512 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in GlaxoSmithKline were worth $4,664,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. Field & Main Bank purchased a new stake in shares of GlaxoSmithKline in the fourth quarter valued at $132,000. Amussen Hunsaker Associates LLC purchased a new stake in shares of GlaxoSmithKline in the fourth quarter valued at $141,000. First Dallas Securities Inc. purchased a new stake in shares of GlaxoSmithKline in the fourth quarter valued at $142,000. Centaurus Financial Inc. purchased a new stake in shares of GlaxoSmithKline in the first quarter valued at $157,000. Finally, Whittier Trust Co. lifted its holdings in shares of GlaxoSmithKline by 71.0% in the first quarter. Whittier Trust Co. now owns 4,520 shares of the pharmaceutical company’s stock valued at $177,000 after purchasing an additional 1,876 shares in the last quarter. Institutional investors own 11.09% of the company’s stock.

GlaxoSmithKline traded up $0.80, reaching $41.94, during midday trading on Thursday, according to Marketbeat. 3,496,218 shares of the company’s stock were exchanged, compared to its average volume of 3,474,794. The stock has a market cap of $102.13 billion, a price-to-earnings ratio of 14.56, a P/E/G ratio of 2.20 and a beta of 0.83. The company has a quick ratio of 0.40, a current ratio of 0.61 and a debt-to-equity ratio of 3.90. GlaxoSmithKline plc has a one year low of $34.52 and a one year high of $44.44.

GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings data on Wednesday, April 25th. The pharmaceutical company reported $0.68 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.70 by ($0.02). The firm had revenue of $10.04 billion for the quarter, compared to analyst estimates of $10.26 billion. GlaxoSmithKline had a return on equity of 144.84% and a net margin of 3.50%. equities research analysts expect that GlaxoSmithKline plc will post 2.84 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 12th. Investors of record on Friday, May 11th will be issued a $0.5298 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 5.05%. The ex-dividend date is Thursday, May 10th. GlaxoSmithKline’s dividend payout ratio is currently 72.92%.

A number of analysts have recently issued reports on GSK shares. Zacks Investment Research upgraded GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $41.00 target price for the company in a report on Thursday, March 22nd. BNP Paribas raised shares of GlaxoSmithKline from a “neutral” rating to an “outperform” rating in a research note on Wednesday, April 4th. Morgan Stanley raised shares of GlaxoSmithKline from an “underweight” rating to an “equal weight” rating in a research note on Thursday, March 22nd. Deutsche Bank reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research note on Monday, April 9th. Finally, Cowen reissued a “hold” rating and set a $40.00 target price on shares of GlaxoSmithKline in a research report on Thursday, February 15th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company’s stock. GlaxoSmithKline currently has an average rating of “Hold” and an average price target of $40.21.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply